{"id":390794,"date":"2017-12-14T00:00:00","date_gmt":"2017-12-14T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0017-2017-biopharma-psoriasis-access-and-reimbursement-us-2017\/"},"modified":"2026-03-31T10:49:14","modified_gmt":"2026-03-31T10:49:14","slug":"acreim0017-2017-biopharma-psoriasis-access-and-reimbursement-us-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0017-2017-biopharma-psoriasis-access-and-reimbursement-us-2017\/","title":{"rendered":"Psoriasis | Access and Reimbursement | US | 2017"},"content":{"rendered":"<p>In the past decade, tumor necrosis factor-alpha (<abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1) inhibitors, AbbVie\u2019s Humira and Amgen\u2019s Enbrel, and Janssen\u2019s interleukin (<abbr title=\"interleukin\">IL<\/abbr>)-12\/23 inhibitor Stelara have been leading the <abbr title=\"United States\">U.S.<\/abbr> psoriasis biologics market. However, the recent wave of <abbr title=\"United States\">U.S.<\/abbr> approvals for novel psoriasis agents\u2014Celgene\u2019s Otezla (2014), Novartis\u2019s Cosentyx (2015), and Eli Lilly\u2019s Taltz (2016)\u2014is anticipated to substantially alter the market landscape. The oral agent Otezla has been successfully carving out a space in the psoriasis treatment algorithm in biologics-naive patients. The more-effective biologics, <abbr title=\"interleukin\">IL<\/abbr>-17 inhibitors Cosentyx and Taltz, are threatening the first-line dominance of <abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1 inhibitors. With the recent and anticipated entry of biosimilars, marketers of psoriasis therapies will learn how they can best overcome the formulary and uptake challenges facing current and emerging therapies in this increasingly competitive market.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What are the current patient-share leaders among psoriasis biologics\/Otezla, and which psoriasis agents do physicians and payers perceive to perform best on specific clinical and market access factors?<\/li>\n<li>How do payers cover\/anticipate covering biosimilar versions of infliximab (Pfizer\u2019s Inflectra) and adalimumab (Amgen\u2019s Amgevita), and what are physicians\u2019 expected prescribing behaviors for\u00a0biosimilars?<\/li>\n<li>What are physician perceptions of emerging biologics, such as brodalumab and guselkumab, and how do payers anticipate covering these novel agents?<\/li>\n<li>What pharmacoeconomic models and data do payers value for examining the cost and efficacy impact of novel psoriasis agents?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION <\/strong><\/p>\n<p>Access &#038; Reimbursement: Provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.<\/p>\n","protected":false},"template":"","class_list":["post-390794","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-psoriasis","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390794","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390794\/revisions"}],"predecessor-version":[{"id":576771,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390794\/revisions\/576771"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390794"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}